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Abstract
Introduction: To explore whether an assay change was responsible for an increasing proportion of patients with
undetectable HIV viral loads at our urban HIV clinic, we selected highly stable patients, examining their viral loads before
and after changing assays. We compared the proportion with detectable viremia during RT-PCR vs. bDNA periods.
Methodology/Principal Findings: We selected patients with $1 viral loads assessed during both RT-PCR and bDNA periods.
We included patients with stable CD4 counts, excluding patients with viral loads $1,000 copies/ml or any significant
changes in therapy. Out of 4500 clinic patients, 419 patients (1588 viral loads) were included. 39% of viral loads were
reported as detectable by RT-PCR vs. 5% reported as detectable by bDNA. The mean coefficient of variation was higher
before vs. after assay change. We found an odds’ ratio of 16.7 for having a viral load .75 copies/ml during the RT-PCR vs.
bDNA periods.
Discussion: These data support previous reports, suggesting that bDNA may more reliably discriminate between viral
suppression and low level viremia in stable patients on therapy. Low-level viremia, noted more with RT-PCR, may promote
unneeded testing, while differences in viral load reliability may impact antiretroviral trial and quality assurance endpoints.
Commonly used plasma separator tubes may differentially affect RT-PCR and bDNA results.
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Introduction
The accurate and reliable quantification of HIV-1 RNA levels,
or plasma viral load (pVL), has become a crucial tool in the
management of HIV disease. Providers use pVL to determine a
patient’s viral set point prior to the initiation of antiretroviral
therapy (ART), to help decide when to initiate therapy, to monitor
response to treatment and to detect treatment failure [1,2]. For
patients on therapy, and for their providers, viral load testing
answers the vital question of whether ART has successfully
suppressed their viremia. Assays used to quantify viral load should
be able to help differentiate patients with adequate viral
suppression (i.e. those who are undetectable) from patients with
low level viremia, who may be failing therapy.
Two assays employed clinically to measure HIV-1 pVL
currently predominate in the U.S., the reverse transcription
polymerase chain reaction assay (RT-PCR) (AMPLICOR HIV-1
MONITOR Ultrasensitive version 1.5, Roche Molecular Systems,
Inc) and the branched chain DNA assay (bDNA, VERSANT
HIV-1 RNA version 3.0 bDNA Assay, Siemens Diagnostics). The
current versions of these assays yield well correlated results
throughout their dynamic ranges [3–5]. Yet, significant test
performance differences exist, including differences in the assays’
reproducibility near their lower limit of quantification (LLOQ) [6–
8].
Peter and Blum report cumulative results for HIV-1 pVL testing
done at a reference lab between January 2000 through December
of 2001, with approximately 4000–7000 tests performed per
month [8]. In September of 2000 their lab changed HIV-1 viral
load assays, from RT-PCR (Roche AMPLICOR, version 1.5) to
bDNA (Bayer VERSANT, version 3.0). They found the bDNA
assay to be more reproducible at low copy numbers (75 copies/ml)
than RT-PCR, with coefficients of variation (CV) of 20% versus
79% respectively [8].
Differing rates of reliability near the LLOQ between the RT-
PCR and bDNA may have important ramifications for individual
patient care. Despite the clinically innocuous nature of intermit-
tent viremia under 200 copies/ml, these ‘‘blips’’ in otherwise stable
patients may promote both patient and practitioner anxiety,
leading to more frequent office visits, more laboratory testing, and
possibly unneeded changes or intensification of anti-retroviral
regimens [9–11]. Additionally, the presence of clinically significant
differences in assay reliability raises the question of whether
clinical trial data are comparable if different pVL assays are
utilized. With the time to loss of virologic response (TLOVR)
clinical trial end point advocated by the Food and Drug
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is defined by two pVL measurements above the HIV RNA assay’s
LLOQ [12]. Trials which utilize RT-PCR may overestimate the
rate of failure due to the assay’s inherent variability near its LLOQ
[13,14].
The John H. Stroger, Jr. Hospital (JSH) of Cook County lab,
which performs HIV-1 pVL testing for the Ruth M. Rothstein
CORE Center, Cook County Health and Hospital System
ambulatory HIV clinic, changed from using a RT-PCR assay to
a bDNA assay in February 2005. During the entire period under
review samples were collected in Plasma Preparation Tubes
(PPTs). Despite the adverse effect that use of PPTs may have on
RT-PCR reliability, they are widely used since they allow
phlebotomy technicians to do a simple centrifugation step before
forwarding specimens to the molecular diagnostics lab. Following
our lab’s change in methodology, our clinic quality assurance
surveillance detected an increase in the proportion of patients with
viral suppression (pVL,75 copies/ml) [11,13].
We utilized a retrospective cohort study, selecting a group of
immunologically stable patients, to determine if significant
differences in the proportion of HIV pVLs reported as detectable
existed between the RT-PCR versus bDNA assays.
Methods
Ethics statement
This research was approved by the Cook County Health and
Hospital System’s (CCHHS) Institutional Review Board. Since
this research entailed the retrospective review of pre-existing data
and because all personal identifying information has been
permanently removed from the study database, the CCHHS
IRB deemed that specific patient informed consent was not
necessary.
We carried out a retrospective, two period review between May
2004 and August 2005, comparing HIV-1 pVL results for a cohort
of highly stable patients. The JSH lab switched from the RT-PCR
to the bDNA HIV pVL assay on February 1
st, 2005. We
conducted a review of the electronic medical record for the CORE
Center’s 4500+ patients. We included and compared all pVLs of
patients who had $1 pVL assessed via RT-PCR (Roche
AMPLICOR HIV-1 MONITOR Ultrasensitive version 1.5,
Roche Molecular Systems, Inc) during eight months prior to
assay change, and via bDNA (VERSANT HIV-1 RNA version 3.0
bDNA Assay, Siemens Diagnostics) during six months after the
change. In order to exclude patients with recent viral decay,
patients had to have at least one undetectable pVL during the six
months prior to entering the review period. To select patients with
viremia related to assay reliability differences, rather than
medication non-adherence or overt virologic failure, we excluded
patients with any pVL measurement $1,000 copies/ml during the
eight month RT-PCR period or the six month bDNA period.
Also, we excluded patients if they had a decrease in absolute CD4
count of $15% during the 14 month review period. We
performed chart reviews, excluding patients with significant
changes in ART either during the 14 month review period, or
three months prior to entering the review period. Decisions
regarding whether to exclude or include patients with changes in
ART were made independent of knowledge of their pVL results.
To assess the assays’ clinical reliability near their LLOQ, as the
primary analysis, we compared the proportion of pVLs reported as
detectable during each of the two periods. Test reliability may be
defined as the extent to which test results remain consistent over
repeat measurements of the same subject under similar conditions.
A test is reliable if it yields consistent results, given stable testing
conditions. It is judged not to be reliable if repeat measurements,
under the same conditions, give different results. For patients in
this stable cohort, all of whom demonstrated previous virologic
suppression, continued on stable ART and maintained steady
CD4 counts, we characterized test reliability by the proportion of
samples with suppressed vs. detectable viremia during the RT-
PCR vs. bDNA periods, with more episodes of detectable, low-
level viremia signifying less clinical reliability near the assays’
LLOQ. To determine an odd’s ratio describing the likelihood for
detectable viremia during the RT-PCR vs. bDNA periods, we
utilized a conditional, fixed-effects, logistic regression model that
accounted for correlation between an individual patient’s multiple
samples (Stata version 9, StataCorpLP, College Station, TX). To
account for RT-PCR’s slightly lower LLOQ (down to pVL of 50)
vs. bDNA (LLOQ down of 75), for analysis purposes, RT-PCR
results between 50 and 75 copies/ml were considered undetect-
able. .
As secondary endpoints, we compared censored mean pVLs
and mean coefficients of variation (CV). In calculating censored
means, we assign undetectable pVLs a value of 49 and 74 copies/
ml for the RT-PCR and bDNA periods. As a sensitivity analysis
we also calculated and report censored means using values of
49 copies/ml and 1 copy/ml for all undetectable pVLs, during
both periods. Coefficients of variation (CV), representing the
standard deviation divided by the mean, were calculated for each
patient with more than one value per period. We report mean
CVs using both censored values and actual values, after the
exclusion of undetectable results. We do not report tests of
statistical significance comparing censored mean pVLs, since the
required left-sided censoring (i.e. undetectable =49, 74 or 1 copy/
ml) is unlikely to reflect the true distribution of pVL values below
the LLOQ. In order to assess utilization of pVL testing, we also
compared mean duration between pVL measurements for the
RT-PCR vs. bDNA periods.
Results
Out of 4500+ clinic patients, 454 patients met initial inclusion
criteria. Following chart review, a total of 419 patients (see Table 1
for clinical/demographic data) and their 1588 pVL measurements
were included for analysis. We excluded 35 patients: 12 due to
documented poor compliance with ART, 10 due to poor therapy
history documentation, 9 related to their charts being at an
inaccessible, off-site location, 2 who were lost to clinical follow-up
but continued to have lab monitoring, and 2 who had ART
discontinued due to medication side effects.
On average, each patient had 3.8 pVLs measured during the 14
month review period. During the RT-PCR period, 322/836 (39%)
pVL values were $75 copies/ml vs. 35/752 (5%) during the
bDNA period (x
2=346, p,0.001) (see Table 1). Figure 1
illustrates pVL distributions for the two periods. By applying a
conditional, fixed-effects, logistic regression model that matched
each patient with him/herself throughout the observation period
we sought to minimize patient introduced variation. We found an
odds ratio of 16.7 (95% CI 10.7–26.1) for having a pVL$75 co-
pies/ml during the RT-PCR vs. bDNA periods.
The sensitivity analysis using different imputed values for
undetectable viral loads demonstrates that using different values
does not affect the finding that RT-PCR has a greater CV in these
stable patients on invariant therapy who entered the observation
period with undetectable pVL (see Table 2). After excluding the
undetectable results, mean CVs were 0.55 (SD=0.37) for the RT-
PCR period vs. 0.19 (SD=0.07) for the bDNA period (t=5.69,
p=0.03), though only two patients had two detectable pVLs
HIV RNA Re-Test Reliability
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calculated. A per patient mean of 101 (SD=31) vs. 104 (SD=31)
days elapsed between pVL measurements during the RT-PCR vs.
bDNA periods (t=1.10, p=0.27).
Discussion
These clinical data, drawn from a large group of immunolog-
ically stable, suppressed patients on established ART demonstrate
that bDNA may more reliably discriminate between viral
suppression and low level viremia in stable patients on therapy.
Previous, similar reports comparing the assays’ reliability lacked
immunologic and treatment data to verify the clinical stability of
patients with low-level viremia [6–8].
Several factors other than differences in assay reliability may
have led to more detectable viremia during the RT-PCR period.
RT-PCR has a lower reported LLOQ and 16% of the detectable
pVLs during the RT-PCR period fell into the 50–75 copies/ml
range. These values were considered undetectable for purposes of
our primary analysis, thereby eliminating any difference mediated
by this disparity in LLOQ. It should also be noted calculating
censored mean pVL levels allowed for the reporting of mean CVs
for the two periods, but it is unlikely that censoring of undetectable
pVLs to an arbitrary, set value reflects the true distribution of
pVLs below the LLOQ. Because of this, the secondary endpoint of
difference in mean CV derived via use of the censored means
should be cautiously interpreted.
Seasonal or time period bias may have contributed to differences
noted in the two assays. Since we included over 400 patients on stable
therapy and close to 1600 observations such effects are unlikely to
have resulted in the magnitude of difference we demonstrated. Also,
because loss of virologic control tends to increase with time, if
anything, time period effects would have led to more detectable
viremia during the chronologically later bDNA period.
The wide use of PPTs, rather than ethylenediaminetetraacetic
acid (EDTA) tubes for collection of pVL specimens has been
linked with false-positive, detectable values, especially when used
with RT-PCR [11]. A study assessing for discordance between
HIV pVL measured via RT-PCR, with specimens collected in
ETDA-containing tubes versus PPTs, under varying processing
protocols, demonstrated that transferring plasma from PPTs to a
separate collection tube prior to specimen freezing eliminated the
discordant, higher levels seen with specimens collected in PPTs vs.
EDTA tubes [14]. These researchers also demonstrated that the
bDNA assay, when compared to the RT-PCR assay, seemed less
affected by the use of PPTs [15]. Giordano and colleagues
evaluated Roche AMPLICOR MONITOR Ultra-sensitive ver-
sions 1.0 and 1.5 RT-PCR results from week 52 patients in a large,
ART clinical trial. They found that 34% fewer patients would be
categorized as virologic responders at week 52, as defined by
having HIV-1 pVL,50 copies/ml, if PPTs vs. EDTA collection
tubes were used [13].
Since we used PPTs during the entire RT-PCR and bDNA
periods, collection tube effects likely influenced RT-PCR and
bDNA assays differently, contributing to the observed differences
in assay reliability near the LLOQ. Because PPTs require less
specimen processing (e.g. no need to remove plasma from cellular
components of sample), their use may improve lab technician
safety and efficiency. Furthermore, clinicians may be unaware of
these collection tube effects or of which collection tube their lab
utilizes. The need to use EDTA tubes for RT-PCR rather than the
more convenient PPTs may, therefore, present an additional
barrier to effective HIV treatment monitoring. The data presented
here demonstrate that bDNA presents a more clinically reliable
Table 1. Clinical/demographic characteristics and viral load
distributions.
N=419
Mean age (years) 45
Sex (% male) 72%
Race/ethnicity
African-American 53%
Hispanic 29%
White 15%
Asian 1%
Other 1%
Unknown 2%
*
Risk factor
Hetero 25%
MSM 24%
Intravenous drug use (IDU) 11%
Peri-natal 2%
IDU/MSM 1%
Transfusion ,1%
Unknown 37%
Mean years with HIV 7.5
Antiretroviral regimen
NRTI backbone +
NNRTI 54%
PI 33%
NNRTI and PI 6%
NRTI a lone 6%
other 1%
Non-excluded change in ART 44/419 (11%)
ART change related to:
Side effect/adverse effect of regimen 35/44 (80%)
Added Hepatitis B activity 3/44 (7%)
Poor CD4 response/intensification 2/44 (5%)
Decrease pill burden 2/44 (5%)
Pregnancy 2/44 (5%
*)
Viral load Distributions
RT-PCR period – number of viral loads 836
,50 copies/ml 453/836 (54%)
50–75 61/836 (7%)
76–200 148/836 (18%)
201–400 90/836 (11%)
.400 84/836 (10%)
bDNA period – number of viral loads 752
,75 copies/ml 717/752 (95%)
75–200 24/752 (3%)
201–400 6/752 (0.8%)
.400 5/752 (0.7%
*)
*Rounding to whole numbers accounts for totals not equal to 100%.
doi:10.1371/journal.pone.0006008.t001
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use PPTs.
The difference we observed in clinical reliability at the lower
end of the assays’ dynamic ranges may have patient-care,
quality assurance, and clinical research implications. While
intermittent viremia of less than 200 copies/ml has been shown
to be innocuous, sustained low-level viremia has been associated
with the emergence of drug resistance [9,16]. It is possible that
t h el o w - l e v e lv i r e m i am o r ef r e quently reported by RT-PCR may
promote unneeded testing and/or medication changes [11].
While the mean time between pVLs measurements did not
differ during the RT-PCR vs. bDNA periods at our institution,
Figure 1. HIV-1 viral loads vs. time. This scatter plot shows each HIV viral load measurement (copies/ml on y-axis) vs. time (x-axis) with a vertical
line dividing the RT-PCR (% per each value) from bNDA (n per each value) time periods. In this figure, undetectable viral loads are censored to
49 copies/ml for the RT-PCR period and to 74 copies/ml for the bDNA period.
doi:10.1371/journal.pone.0006008.g001
Table 2. Mean censored viral loads and coefficients of variation.
Undetectable to 49 copies/ml Undetectable to 74 copies/ml Undetectable to 1 copy/ml
Mean pVL RT-PCR period (SD), copies/ml 149 (187) Not calculated
* 123 (203)
Mean pVL bDNA period (SD), copies/ml 57 (62) 81 (59) 12 (69)
Mean CV RT-PCR period (SD) 0.48 (0.45) Not calculated
* 0.76 (0.66)
Mean CV bDNA period (SD) 0.05 (0.19) 0.03 (0.14) 0.12 (0.41)
*Value not calculated because RT-PCR LLOQ=50 copies/ml, so for RT-PCR for values.50 actual, rather than censored values used in calculating means. We do not
report tests of statistical significance comparing censored mean pVLs, since the required left-sided censoring (i.e. undetectable=49, 74 or 1 copy/ml) is unlikely to
reflect the true distribution of pVL values below the LLOQ.
doi:10.1371/journal.pone.0006008.t002
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have led to differences in other, more difficult to measure
outcomes, such as visit length and provider and/or patient
anxiety.
Proportions of patients with undetectable viral loads are
important benchmarks in clinical science and quality assurance.
Since antiretroviral registrational trials utilize the TLOVR
endpoint, RT-PCR’s inferior reliability near the LLOQ, especially
when using PPTs, may both inflate virologic failure rates and
confound efforts to compare failure rates between trials [12–14].
Furthermore, comparing rates of HIV viral suppression between
clinical care settings which use different assays should be
approached with caution. Differences in the proportion of
undetectable patients in clinics using bDNA vs. RT-PCR should
be expected. Health insurers, state and federal payors, and federal
funders who conduct benchmarking or quality assurance compar-
isons must be made aware of these differences when comparing
clinical outcomes.
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